Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes
Real-TICA
Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes. Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS.
1 other identifier
observational
700
1 country
6
Brief Summary
Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2014
Typical duration for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
October 9, 2014
CompletedFirst Posted
Study publicly available on registry
October 15, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedJune 14, 2018
February 1, 2017
2.3 years
October 9, 2014
June 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Treatment outcomes of ACS patients receiving Ticagrelor
Documentation of Events for ACS patients treated with Ticagrelor with follow-up over 12 months
12 months
Secondary Outcomes (1)
Long-term use and premature discontinuation of Ticagrelor treatment
12 months
Interventions
Eligibility Criteria
All patients from the ALKK-PCI registry discharged alive after PCI for ACS (STEMI and NSTE-ACS) and treated with ticagrelor during the acute phase.
You may qualify if:
- Age \> 18
- ACS (STEMI or NSTE-ACS) with PCI
- Ticagrelor treatment during the acute phase
- Written informed consent for participation in the study.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Zentralklinik Bad Berka GmbH
Bad Berka, 99437, Germany
Vivantes-Klinikum Neukölln
Berlin, 12351, Germany
Klinikum Hildesheim GmbH
Hildesheim, 31135, Germany
Krankenhaus Landshut-Achdorf
Landshut, 84036, Germany
Klinikum Ludwigshafen
Ludwigshafen, Germany
Klinikum-Wetzlar Braunsfeld
Wetzlar, 35578, Germany
Related Publications (1)
Zeymer U, Cully M, Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):205-210. doi: 10.1093/ehjcvp/pvy018.
PMID: 29878086RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Uwe Zeymer, Prof. Dr.
Klinikum Ludwigshafen, Stiftung IHF - Institut für Herzinfarktforschung
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 9, 2014
First Posted
October 15, 2014
Study Start
August 1, 2014
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
June 14, 2018
Record last verified: 2017-02